{"id":365030,"date":"2025-09-01T04:36:18","date_gmt":"2025-09-01T04:36:18","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-arrivent-biopharma\/"},"modified":"2025-09-01T04:36:18","modified_gmt":"2025-09-01T04:36:18","slug":"how-to-buy-arrivent-biopharma","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/","title":{"rendered":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-365030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"ArriVent BioPharma (AVBP) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $19.21, analist hedefleri $45'e kadar ve potansiyel b\u00fcy\u00fcme i\u00e7in 2026'n\u0131n \u00f6nemli kataliz\u00f6r\u00fc.","description_source":{"label":"Description","type":"textarea","formatted_value":"ArriVent BioPharma (AVBP) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $19.21, analist hedefleri $45'e kadar ve potansiyel b\u00fcy\u00fcme i\u00e7in 2026'n\u0131n \u00f6nemli kataliz\u00f6r\u00fc."},"intro":"Patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeline sahip bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? ArriVent BioPharma, bug\u00fcn onkoloji ila\u00e7 geli\u015ftirmede en heyecan verici f\u0131rsatlardan birini temsil ediyor. \u00d6nc\u00fc ila\u00e7 adaylar\u0131 kritik Faz 3 sonu\u00e7lar\u0131na yakla\u015f\u0131rken ve analistler b\u00fcy\u00fck bir y\u00fckseli\u015f \u00f6ng\u00f6r\u00fcrken, bu b\u00fcy\u00fck hareketten \u00f6nce pozisyon alma \u015fans\u0131n\u0131z olabilir. AVBP hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeline sahip bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? ArriVent BioPharma, bug\u00fcn onkoloji ila\u00e7 geli\u015ftirmede en heyecan verici f\u0131rsatlardan birini temsil ediyor. \u00d6nc\u00fc ila\u00e7 adaylar\u0131 kritik Faz 3 sonu\u00e7lar\u0131na yakla\u015f\u0131rken ve analistler b\u00fcy\u00fck bir y\u00fckseli\u015f \u00f6ng\u00f6r\u00fcrken, bu b\u00fcy\u00fck hareketten \u00f6nce pozisyon alma \u015fans\u0131n\u0131z olabilir. AVBP hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Hareketi<\/h2> <p>1 Eyl\u00fcl 2025 itibar\u0131yla ArriVent BioPharma (AVBP) hisseleri <strong>19,21 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi son zamanlarda \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve 52 haftal\u0131k aral\u0131kta 15,47 $ ile 36,37 $ aras\u0131nda i\u015flem g\u00f6rerek klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc dramatik dalgalanmalar\u0131 g\u00f6sterdi.<\/p> <p><strong>Takviminize not edin: 13 Kas\u0131m 2025<\/strong>, ArriVent'in 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 kritik tarih. Tarihsel olarak, biyoteknoloji kazan\u00e7 raporlar\u0131 b\u00fcy\u00fck fiyat hareketlerine - hem yukar\u0131 hem a\u015fa\u011f\u0131 - neden olabilir.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>ArriVent'in finansal g\u00fcncellemelerine piyasa tepkilerine bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li><strong>11 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin alt\u0131nda, hisse ba\u015f\u0131na 0,90 $ zarar, beklenen 0,71 $ zarar. Hisse hemen %3,2 d\u00fc\u015ft\u00fc ancak yat\u0131r\u0131mc\u0131lar g\u00fc\u00e7l\u00fc nakit pozisyonuna odaklan\u0131nca birka\u00e7 g\u00fcn i\u00e7inde toparland\u0131<\/li> <li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek sonu\u00e7lar\u0131 Ar-Ge harcamalar\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 ancak nakit rezervinin korundu\u011funu g\u00f6sterdi. Hisse ba\u015flang\u0131\u00e7ta d\u00fc\u015ft\u00fc, ard\u0131ndan olumlu klinik deneme g\u00fcncellemeleriyle y\u00fckseldi<\/li> <li><strong>\u015eubat 2025<\/strong>: Y\u0131l sonu sonu\u00e7lar\u0131 Faz 3 denemeleri i\u00e7in hasta kayd\u0131nda ilerlemeyi vurgulad\u0131. Hisse, deneme takvimleri hakk\u0131ndaki iyimserlikle %8 kazand\u0131<\/li> <\/ul> <p>Model, kazan\u00e7lar\u0131n ka\u00e7\u0131r\u0131lmas\u0131n\u0131n k\u0131sa vadeli bask\u0131 yaratt\u0131\u011f\u0131n\u0131 ancak piyasan\u0131n h\u0131zla \u00e7eyreklik kay\u0131tlardan ziyade klinik d\u00f6n\u00fcm noktalar\u0131na ve nakit pozisyonuna odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>ArriVent hisseleri son alt\u0131 ayda adeta bir h\u0131z treni yolculu\u011fu ya\u015fad\u0131:<\/p> <ul> <li><strong>Mart 2025<\/strong>: Faz 3 hasta kayd\u0131 tamamlan\u0131rken 23-24 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Nisan 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 21-22 $ aral\u0131\u011f\u0131na \u00e7ekildi<\/li> <li><strong>May\u0131s 2025<\/strong>: Olumlu analist y\u00fckseltmeleri ve ortakl\u0131k haberleriyle 25 $ \u00fczeri rallisi<\/li> <li><strong>Haziran 2025<\/strong>: Kurumsal ilginin artmas\u0131yla 26-27 $ civar\u0131nda zirve<\/li> <li><strong>Temmuz 2025<\/strong>: Piyasa volatilitesi nedeniyle 21-22 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f<\/li> <li><strong>A\u011fustos 2025<\/strong>: Kazan\u00e7 sonras\u0131 mevcut 19 $ seviyesine daha fazla d\u00fc\u015f\u00fc\u015f<\/li> <\/ul> <p>Genel trend <strong>Haziran zirvesinden %17 d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6steriyor, ancak bu geri \u00e7ekilme bir\u00e7ok analiste g\u00f6re hisseyi a\u015f\u0131r\u0131 sat\u0131lm\u0131\u015f olarak g\u00f6r\u00fcp cazip bir giri\u015f noktas\u0131 yarat\u0131yor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 28-32 $ aral\u0131\u011f\u0131 (2026 ba\u015f\u0131nda Faz 3 verileri beklentisi) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li> <li><strong>2026 Hedefi<\/strong>: 38-45 $ (2026 ba\u015f\u0131nda Faz 3 verileri pozitif olursa)<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 55-65 $ (ba\u015far\u0131l\u0131 ticarile\u015fme ve geni\u015fletilmi\u015f endikasyonlar varsay\u0131larak)<\/li> <li><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 75 $+ (EGFR mutasyon tedavilerinde potansiyel pazar liderli\u011fi)<\/li> <\/ul> <p>8 analistin ortak g\u00f6r\u00fc\u015f\u00fc a\u015f\u0131r\u0131 iyimser olup, ortalama fiyat hedefi 39,14 $ ile mevcut seviyelerden <strong>%104 y\u00fckseli\u015f potansiyeli<\/strong> sunuyor. Goldman Sachs (33 $ hedef), HC Wainwright (42 $) ve B. Riley (G\u00fc\u00e7l\u00fc Al) \u00f6nemli b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fcyor.<\/p> <h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken \u00d6nemli Yat\u0131r\u0131m Riskleri<\/h2> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: En b\u00fcy\u00fck tehlike - firmonertinib Faz 3 verileri 2026 ba\u015f\u0131nda hayal k\u0131r\u0131kl\u0131\u011f\u0131 yarat\u0131rsa, hisse %50-70 d\u00fc\u015febilir<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: Pozitif verilere ra\u011fmen FDA onay\u0131 garanti de\u011fil. Gecikmeler veya ek deneme gereksinimleri zaman \u00e7izelgesini uzatabilir<\/li> <li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: \u015eu anda 2027 ortas\u0131na kadar iyi finanse edilmi\u015f olsa da, ek sermaye art\u0131r\u0131mlar\u0131 mevcut hissedarlar\u0131 seyreltebilir<\/li> <li><strong>Rekabet Ortam\u0131<\/strong>: Di\u011fer \u015firketler benzer EGFR inhibit\u00f6rleri geli\u015ftiriyor, ancak ArriVent'in beyin penetrasyon \u00f6zellikleri avantaj sa\u011flayabilir<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle genel piyasa endekslerinden 2-3 kat daha volatil<\/li> <\/ul> <h2>\ud83d\udfe2 Pozitif Sinyaller ve B\u00fcy\u00fcme Kataliz\u00f6rleri<\/h2> <ul> <li><strong>Hemen Beklenen Kataliz\u00f6rler (2025-2026)<\/strong>:   <ul>     <li>Faz 3 FURVENT ana verileri 2026 ba\u015f\u0131nda bekleniyor - potansiyel ikili olay<\/li>     <li>Ek analist kapsam\u0131 ve potansiyel endeks dahil edilmesi<\/li>     <li>\u00c7in d\u0131\u015f\u0131 ticarile\u015fme i\u00e7in ortakl\u0131k duyurular\u0131<\/li>   <\/ul> <\/li> <li><strong>Mali G\u00fc\u00e7<\/strong>: 254,5 milyon $ nakit pozisyonu, 2027 ortas\u0131na kadar sermaye art\u0131r\u0131m\u0131 olmadan finansman sa\u011fl\u0131yor<\/li> <li><strong>Reg\u00fclasyon Avantajlar\u0131<\/strong>: FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Terapi ve Yetim \u0130la\u00e7 tan\u0131mlar\u0131 h\u0131zland\u0131r\u0131lm\u0131\u015f onay yollar\u0131 sunuyor<\/li> <li><strong>Pazar F\u0131rsat\u0131<\/strong>: EGFR exon20 insersiyonlu NSCLC, s\u0131n\u0131rl\u0131 rekabetle 2-3 milyar $ k\u00fcresel pazar f\u0131rsat\u0131 sunuyor<\/li> <li><strong>Analist Deste\u011fi<\/strong>: Fiyat hedefleri %100+ y\u00fckseli\u015f \u00f6ng\u00f6ren oybirli\u011fiyle G\u00fc\u00e7l\u00fc Al dereceleri<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Ciddi \u00d6neriler<\/strong>:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar-maliyet ortalamas\u0131 kullan\u0131n<\/strong> - Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - Daha iyi giri\u015f noktalar\u0131 i\u00e7in 18 $ alt\u0131 d\u00fc\u015f\u00fc\u015fleri izleyin<\/li> <li><strong>\u00c7\u0131k\u0131\u015f stratejisi belirleyin<\/strong> - \u0130\u015fleme girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li> <\/ol> <p><strong>Esprili deneyimli tavsiye<\/strong>: \"AVBP ticareti yapmak bir klinik deneme izlemek gibidir - %90 s\u0131k\u0131c\u0131l\u0131k ve %10 saf adrenalin. Veriler d\u00fc\u015ft\u00fc\u011f\u00fcnde CPR'ye ihtiyac\u0131 olan siz olmay\u0131n!\"<\/p> <h2>\u2705 Ad\u0131m Ad\u0131m: ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ listeleri ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Uyumluluk i\u00e7in gerekli belgeleri sa\u011flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"AVBP\" aramas\u0131 yap\u0131n<\/td><td>ArriVent BioPharma i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131 kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve toplam maliyeti onaylamadan \u00f6nce kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td><td>Ger\u00e7ekle\u015fme fiyat\u0131n\u0131 limit emrinizle kar\u015f\u0131la\u015ft\u0131rarak izleyin<\/td><\/tr> <tr><td>8<\/td><td>Portf\u00f6y takibi kurun<\/td><td>Haberler ve fiyat hareketleri i\u00e7in uyar\u0131lar kullan\u0131n<\/td><\/tr> <tr><td>9<\/td><td>Tutma s\u00fcrenizi planlay\u0131n<\/td><td>Biyoteknoloji yat\u0131r\u0131mlar\u0131 genellikle 12-24 ayl\u0131k vadeler gerektirir<\/td><\/tr> <tr><td>10<\/td><td>Pozisyonu d\u00fczenli g\u00f6zden ge\u00e7irin<\/td><td>Klinik deneme g\u00fcncellemelerine g\u00f6re stratejinizi ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option, piyasaya giri\u015fin eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m<\/strong>: Sadece 5 $ ile ger\u00e7ek piyasa maruziyetiyle stratejileri test etmeye ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC s\u00fcreci dakikalar i\u00e7inde tamamlan\u0131r<\/li> <li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri ve ticaret e\u011fitimi sa\u011flar<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engeli, AVBP gibi belirli hisselere daha b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce deneyim kazanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te ArriVent BioPharma: Onkoloji \u0130novasyon Lideri<\/h2> <p>ArriVent BioPharma, \u00f6zellikle zor tedavi edilen EGFR mutasyonlar\u0131na sahip k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde hedefe y\u00f6nelik kanser tedavisi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. 2021'de kurulan \u015firket, \u00f6nc\u00fc aday\u0131 firmonertinib'i klinik geli\u015ftirmede ola\u011fan\u00fcst\u00fc h\u0131zla ilerletti.<\/p> <p>\u015eirketin i\u015f modeli, umut vadeden ila\u00e7 adaylar\u0131n\u0131 lisanslay\u0131p derin onkoloji uzmanl\u0131\u011f\u0131n\u0131 kullanarak k\u00fcresel potansiyellerini maksimize etmeye odaklan\u0131r. Firmonertinib \u00c7in'de belirli EGFR mutasyonlar\u0131 i\u00e7in onaylanm\u0131\u015f olup, ArriVent \u015fimdi ABD ve k\u00fcresel onay i\u00e7in zorlu exon20 insersiyon mutasyon pop\u00fclasyonunu hedeflemektedir.<\/p> <ul> <li><strong>G\u00fcncel Piyasa Konumu<\/strong>: 779 milyon $ piyasa de\u011feri ve g\u00fc\u00e7l\u00fc kurumsal sahiplik<\/li> <li><strong>Nakit Rezervi<\/strong>: 254,5 milyon $ ile 2027 ortas\u0131na kadar finansman sa\u011flan\u0131yor<\/li> <li><strong>Klinik A\u015fama<\/strong>: \u00d6nc\u00fc aday i\u00e7in 2026 ba\u015f\u0131nda Faz 3 verileri bekleniyor<\/li> <li><strong>Analist Kapsam\u0131<\/strong>: 8 firma oybirli\u011fiyle G\u00fc\u00e7l\u00fc Al dereceleri vermi\u015f<\/li> <\/ul> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: ArriVent'in Faz 3 FURVENT denemesi, nadir mutasyon pop\u00fclasyonunu hedeflemesine ra\u011fmen y\u0131l\u0131n en h\u0131zl\u0131 k\u00fcresel onkoloji deneme kay\u0131tlar\u0131ndan biri olarak d\u00f6rt k\u0131tada 398 hastan\u0131n kayd\u0131n\u0131 rekor s\u00fcrede tamamlad\u0131.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Hareketi<\/h2>\n<p>1 Eyl\u00fcl 2025 itibar\u0131yla ArriVent BioPharma (AVBP) hisseleri <strong>19,21 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi son zamanlarda \u00f6nemli dalgalanmalar ya\u015fad\u0131 ve 52 haftal\u0131k aral\u0131kta 15,47 $ ile 36,37 $ aras\u0131nda i\u015flem g\u00f6rerek klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc dramatik dalgalanmalar\u0131 g\u00f6sterdi.<\/p>\n<p><strong>Takviminize not edin: 13 Kas\u0131m 2025<\/strong>, ArriVent&#8217;in 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 kritik tarih. Tarihsel olarak, biyoteknoloji kazan\u00e7 raporlar\u0131 b\u00fcy\u00fck fiyat hareketlerine &#8211; hem yukar\u0131 hem a\u015fa\u011f\u0131 &#8211; neden olabilir.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>ArriVent&#8217;in finansal g\u00fcncellemelerine piyasa tepkilerine bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li><strong>11 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin alt\u0131nda, hisse ba\u015f\u0131na 0,90 $ zarar, beklenen 0,71 $ zarar. Hisse hemen %3,2 d\u00fc\u015ft\u00fc ancak yat\u0131r\u0131mc\u0131lar g\u00fc\u00e7l\u00fc nakit pozisyonuna odaklan\u0131nca birka\u00e7 g\u00fcn i\u00e7inde toparland\u0131<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek sonu\u00e7lar\u0131 Ar-Ge harcamalar\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 ancak nakit rezervinin korundu\u011funu g\u00f6sterdi. Hisse ba\u015flang\u0131\u00e7ta d\u00fc\u015ft\u00fc, ard\u0131ndan olumlu klinik deneme g\u00fcncellemeleriyle y\u00fckseldi<\/li>\n<li><strong>\u015eubat 2025<\/strong>: Y\u0131l sonu sonu\u00e7lar\u0131 Faz 3 denemeleri i\u00e7in hasta kayd\u0131nda ilerlemeyi vurgulad\u0131. Hisse, deneme takvimleri hakk\u0131ndaki iyimserlikle %8 kazand\u0131<\/li>\n<\/ul>\n<p>Model, kazan\u00e7lar\u0131n ka\u00e7\u0131r\u0131lmas\u0131n\u0131n k\u0131sa vadeli bask\u0131 yaratt\u0131\u011f\u0131n\u0131 ancak piyasan\u0131n h\u0131zla \u00e7eyreklik kay\u0131tlardan ziyade klinik d\u00f6n\u00fcm noktalar\u0131na ve nakit pozisyonuna odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>ArriVent hisseleri son alt\u0131 ayda adeta bir h\u0131z treni yolculu\u011fu ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: Faz 3 hasta kayd\u0131 tamamlan\u0131rken 23-24 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Nisan 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 21-22 $ aral\u0131\u011f\u0131na \u00e7ekildi<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Olumlu analist y\u00fckseltmeleri ve ortakl\u0131k haberleriyle 25 $ \u00fczeri rallisi<\/li>\n<li><strong>Haziran 2025<\/strong>: Kurumsal ilginin artmas\u0131yla 26-27 $ civar\u0131nda zirve<\/li>\n<li><strong>Temmuz 2025<\/strong>: Piyasa volatilitesi nedeniyle 21-22 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Kazan\u00e7 sonras\u0131 mevcut 19 $ seviyesine daha fazla d\u00fc\u015f\u00fc\u015f<\/li>\n<\/ul>\n<p>Genel trend <strong>Haziran zirvesinden %17 d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6steriyor, ancak bu geri \u00e7ekilme bir\u00e7ok analiste g\u00f6re hisseyi a\u015f\u0131r\u0131 sat\u0131lm\u0131\u015f olarak g\u00f6r\u00fcp cazip bir giri\u015f noktas\u0131 yarat\u0131yor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 28-32 $ aral\u0131\u011f\u0131 (2026 ba\u015f\u0131nda Faz 3 verileri beklentisi) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/li>\n<li><strong>2026 Hedefi<\/strong>: 38-45 $ (2026 ba\u015f\u0131nda Faz 3 verileri pozitif olursa)<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 55-65 $ (ba\u015far\u0131l\u0131 ticarile\u015fme ve geni\u015fletilmi\u015f endikasyonlar varsay\u0131larak)<\/li>\n<li><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 75 $+ (EGFR mutasyon tedavilerinde potansiyel pazar liderli\u011fi)<\/li>\n<\/ul>\n<p>8 analistin ortak g\u00f6r\u00fc\u015f\u00fc a\u015f\u0131r\u0131 iyimser olup, ortalama fiyat hedefi 39,14 $ ile mevcut seviyelerden <strong>%104 y\u00fckseli\u015f potansiyeli<\/strong> sunuyor. Goldman Sachs (33 $ hedef), HC Wainwright (42 $) ve B. Riley (G\u00fc\u00e7l\u00fc Al) \u00f6nemli b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fcyor.<\/p>\n<h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken \u00d6nemli Yat\u0131r\u0131m Riskleri<\/h2>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: En b\u00fcy\u00fck tehlike &#8211; firmonertinib Faz 3 verileri 2026 ba\u015f\u0131nda hayal k\u0131r\u0131kl\u0131\u011f\u0131 yarat\u0131rsa, hisse %50-70 d\u00fc\u015febilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: Pozitif verilere ra\u011fmen FDA onay\u0131 garanti de\u011fil. Gecikmeler veya ek deneme gereksinimleri zaman \u00e7izelgesini uzatabilir<\/li>\n<li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: \u015eu anda 2027 ortas\u0131na kadar iyi finanse edilmi\u015f olsa da, ek sermaye art\u0131r\u0131mlar\u0131 mevcut hissedarlar\u0131 seyreltebilir<\/li>\n<li><strong>Rekabet Ortam\u0131<\/strong>: Di\u011fer \u015firketler benzer EGFR inhibit\u00f6rleri geli\u015ftiriyor, ancak ArriVent&#8217;in beyin penetrasyon \u00f6zellikleri avantaj sa\u011flayabilir<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle genel piyasa endekslerinden 2-3 kat daha volatil<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Pozitif Sinyaller ve B\u00fcy\u00fcme Kataliz\u00f6rleri<\/h2>\n<ul>\n<li><strong>Hemen Beklenen Kataliz\u00f6rler (2025-2026)<\/strong>:\n<ul>\n<li>Faz 3 FURVENT ana verileri 2026 ba\u015f\u0131nda bekleniyor &#8211; potansiyel ikili olay<\/li>\n<li>Ek analist kapsam\u0131 ve potansiyel endeks dahil edilmesi<\/li>\n<li>\u00c7in d\u0131\u015f\u0131 ticarile\u015fme i\u00e7in ortakl\u0131k duyurular\u0131<\/li>\n<\/ul>\n<\/li>\n<li><strong>Mali G\u00fc\u00e7<\/strong>: 254,5 milyon $ nakit pozisyonu, 2027 ortas\u0131na kadar sermaye art\u0131r\u0131m\u0131 olmadan finansman sa\u011fl\u0131yor<\/li>\n<li><strong>Reg\u00fclasyon Avantajlar\u0131<\/strong>: FDA H\u0131zland\u0131r\u0131lm\u0131\u015f Terapi ve Yetim \u0130la\u00e7 tan\u0131mlar\u0131 h\u0131zland\u0131r\u0131lm\u0131\u015f onay yollar\u0131 sunuyor<\/li>\n<li><strong>Pazar F\u0131rsat\u0131<\/strong>: EGFR exon20 insersiyonlu NSCLC, s\u0131n\u0131rl\u0131 rekabetle 2-3 milyar $ k\u00fcresel pazar f\u0131rsat\u0131 sunuyor<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: Fiyat hedefleri %100+ y\u00fckseli\u015f \u00f6ng\u00f6ren oybirli\u011fiyle G\u00fc\u00e7l\u00fc Al dereceleri<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Ciddi \u00d6neriler<\/strong>:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar-maliyet ortalamas\u0131 kullan\u0131n<\/strong> &#8211; Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; Daha iyi giri\u015f noktalar\u0131 i\u00e7in 18 $ alt\u0131 d\u00fc\u015f\u00fc\u015fleri izleyin<\/li>\n<li><strong>\u00c7\u0131k\u0131\u015f stratejisi belirleyin<\/strong> &#8211; \u0130\u015fleme girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li>\n<\/ol>\n<p><strong>Esprili deneyimli tavsiye<\/strong>: &#8220;AVBP ticareti yapmak bir klinik deneme izlemek gibidir &#8211; %90 s\u0131k\u0131c\u0131l\u0131k ve %10 saf adrenalin. Veriler d\u00fc\u015ft\u00fc\u011f\u00fcnde CPR&#8217;ye ihtiyac\u0131 olan siz olmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Ad\u0131m Ad\u0131m: ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Uyumluluk i\u00e7in gerekli belgeleri sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;AVBP&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>ArriVent BioPharma i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve toplam maliyeti onaylamadan \u00f6nce kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td>\n<td>Ger\u00e7ekle\u015fme fiyat\u0131n\u0131 limit emrinizle kar\u015f\u0131la\u015ft\u0131rarak izleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Portf\u00f6y takibi kurun<\/td>\n<td>Haberler ve fiyat hareketleri i\u00e7in uyar\u0131lar kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Tutma s\u00fcrenizi planlay\u0131n<\/td>\n<td>Biyoteknoloji yat\u0131r\u0131mlar\u0131 genellikle 12-24 ayl\u0131k vadeler gerektirir<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Pozisyonu d\u00fczenli g\u00f6zden ge\u00e7irin<\/td>\n<td>Klinik deneme g\u00fcncellemelerine g\u00f6re stratejinizi ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option, piyasaya giri\u015fin eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m<\/strong>: Sadece 5 $ ile ger\u00e7ek piyasa maruziyetiyle stratejileri test etmeye ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC s\u00fcreci dakikalar i\u00e7inde tamamlan\u0131r<\/li>\n<li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri ve ticaret e\u011fitimi sa\u011flar<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engeli, AVBP gibi belirli hisselere daha b\u00fcy\u00fck miktarlar yat\u0131rmadan \u00f6nce deneyim kazanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te ArriVent BioPharma: Onkoloji \u0130novasyon Lideri<\/h2>\n<p>ArriVent BioPharma, \u00f6zellikle zor tedavi edilen EGFR mutasyonlar\u0131na sahip k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde hedefe y\u00f6nelik kanser tedavisi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. 2021&#8217;de kurulan \u015firket, \u00f6nc\u00fc aday\u0131 firmonertinib&#8217;i klinik geli\u015ftirmede ola\u011fan\u00fcst\u00fc h\u0131zla ilerletti.<\/p>\n<p>\u015eirketin i\u015f modeli, umut vadeden ila\u00e7 adaylar\u0131n\u0131 lisanslay\u0131p derin onkoloji uzmanl\u0131\u011f\u0131n\u0131 kullanarak k\u00fcresel potansiyellerini maksimize etmeye odaklan\u0131r. Firmonertinib \u00c7in&#8217;de belirli EGFR mutasyonlar\u0131 i\u00e7in onaylanm\u0131\u015f olup, ArriVent \u015fimdi ABD ve k\u00fcresel onay i\u00e7in zorlu exon20 insersiyon mutasyon pop\u00fclasyonunu hedeflemektedir.<\/p>\n<ul>\n<li><strong>G\u00fcncel Piyasa Konumu<\/strong>: 779 milyon $ piyasa de\u011feri ve g\u00fc\u00e7l\u00fc kurumsal sahiplik<\/li>\n<li><strong>Nakit Rezervi<\/strong>: 254,5 milyon $ ile 2027 ortas\u0131na kadar finansman sa\u011flan\u0131yor<\/li>\n<li><strong>Klinik A\u015fama<\/strong>: \u00d6nc\u00fc aday i\u00e7in 2026 ba\u015f\u0131nda Faz 3 verileri bekleniyor<\/li>\n<li><strong>Analist Kapsam\u0131<\/strong>: 8 firma oybirli\u011fiyle G\u00fc\u00e7l\u00fc Al dereceleri vermi\u015f<\/li>\n<\/ul>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: ArriVent&#8217;in Faz 3 FURVENT denemesi, nadir mutasyon pop\u00fclasyonunu hedeflemesine ra\u011fmen y\u0131l\u0131n en h\u0131zl\u0131 k\u00fcresel onkoloji deneme kay\u0131tlar\u0131ndan biri olarak d\u00f6rt k\u0131tada 398 hastan\u0131n kayd\u0131n\u0131 rekor s\u00fcrede tamamlad\u0131.<\/p>\n"},"faq":[{"question":"ArriVent BioPharma hisseleri nereden al\u0131nabilir?","answer":"ArriVent BioPharma hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve i\u015flem platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"AVBP hisseleri i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz i\u015flem platformuna ba\u011fl\u0131d\u0131r, ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck bir miktarla ba\u015flayabilirsiniz."},{"question":"ArriVent BioPharma'n\u0131n klinik deneme sonu\u00e7lar\u0131 ne zaman a\u00e7\u0131klanacak?","answer":"\u00d6nc\u00fc ila\u00e7 aday\u0131n\u0131n Faz 3 sonu\u00e7lar\u0131 2026 y\u0131l\u0131n\u0131n ba\u015flar\u0131nda a\u00e7\u0131klanmas\u0131 beklenmektedir."},{"question":"AVBP hisseleri i\u00e7in analistlerin fiyat hedefleri nedir?","answer":"Analistler 2026 i\u00e7in 38-45 $ aral\u0131\u011f\u0131nda hedef fiyatlar belirlemi\u015f olup, ortalama fiyat hedefi 39,14 $ seviyesindedir."},{"question":"ArriVent BioPharma yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, reg\u00fclasyon gecikmeleri, nakit t\u00fcketimi, rekabet ve piyasa volatilitesi bulunmaktad\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"ArriVent BioPharma hisseleri nereden al\u0131nabilir?","answer":"ArriVent BioPharma hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve i\u015flem platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"AVBP hisseleri i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz i\u015flem platformuna ba\u011fl\u0131d\u0131r, ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck bir miktarla ba\u015flayabilirsiniz."},{"question":"ArriVent BioPharma'n\u0131n klinik deneme sonu\u00e7lar\u0131 ne zaman a\u00e7\u0131klanacak?","answer":"\u00d6nc\u00fc ila\u00e7 aday\u0131n\u0131n Faz 3 sonu\u00e7lar\u0131 2026 y\u0131l\u0131n\u0131n ba\u015flar\u0131nda a\u00e7\u0131klanmas\u0131 beklenmektedir."},{"question":"AVBP hisseleri i\u00e7in analistlerin fiyat hedefleri nedir?","answer":"Analistler 2026 i\u00e7in 38-45 $ aral\u0131\u011f\u0131nda hedef fiyatlar belirlemi\u015f olup, ortalama fiyat hedefi 39,14 $ seviyesindedir."},{"question":"ArriVent BioPharma yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, reg\u00fclasyon gecikmeleri, nakit t\u00fcketimi, rekabet ve piyasa volatilitesi bulunmaktad\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T04:36:18+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-09-01T04:36:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\",\"name\":\"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-09-01T04:36:18+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/","og_locale":"tr_TR","og_type":"article","og_title":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-01T04:36:18+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-09-01T04:36:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/","name":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r - ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-09-01T04:36:18+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrivent-biopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"ArriVent BioPharma, Inc. (AVBP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ArriVent BioPharma, Inc. (AVBP) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":365033,"slug":"how-to-buy-arrivent-biopharma","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu ArriVent BioPharma, Inc. (AVBP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu ArriVent BioPharma, Inc. (AVBP)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arrivent-biopharma\/"},"pt_AA":{"locale":"pt_AA","id":365028,"slug":"how-to-buy-arrivent-biopharma","post_title":"Como comprar a\u00e7\u00f5es da ArriVent BioPharma, Inc. (AVBP) - Investimento em a\u00e7\u00f5es da ArriVent BioPharma, Inc. (AVBP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arrivent-biopharma\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/365030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=365030"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/365030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=365030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=365030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=365030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}